Definition:Regulatory due diligence
🔎 Regulatory due diligence is the investigative workstream within an insurance transaction that examines the target's compliance with applicable insurance regulatory requirements, the status of its licenses and authorizations, its supervisory history, and the regulatory implications of the proposed deal for both buyer and target. Given that insurance companies operate under some of the most intensive supervisory regimes of any financial sector — with requirements spanning solvency, conduct, anti-money laundering, and governance — regulatory due diligence often determines whether a transaction can proceed at all, and on what terms.
⚙️ The scope typically encompasses several core areas: verification that the target holds valid licenses in every jurisdiction where it writes or services business; review of all correspondence with supervisory authorities, including any enforcement actions, supervisory letters, or remediation plans; assessment of compliance with capital adequacy requirements (whether under Solvency II, the NAIC RBC framework, C-ROSS, or other local regimes); analysis of fit and proper approvals for directors and key function holders; and evaluation of the change of control approval pathway. For targets that operate as MGAs or coverholders, the review extends to delegated authority arrangements and the regulatory status of those agreements in each relevant market. The diligence team — usually comprising specialist insurance regulatory lawyers in each jurisdiction, supplemented by compliance consultants — works from materials in the data room and the Q&A log, and may also conduct direct inquiries with regulators where permitted.
💡 Regulatory due diligence findings can reshape a deal's structure, pricing, and risk allocation in fundamental ways. Discovery that a target has been operating without a required license in a given market, or that it faces a pending supervisory investigation into claims handling practices, can trigger purchase price reductions, enhanced indemnity protections, or even deal termination. In cross-border insurance transactions, the complexity multiplies: an acquirer purchasing an insurer with subsidiaries in the EU, the U.S., and Asia must navigate overlapping and sometimes conflicting regulatory expectations. The findings feed into the regulatory due diligence report and directly inform the regulatory approval application strategy, making this workstream one of the highest-priority threads in any insurance deal process.
Related concepts: